{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:43:28Z","timestamp":1759178608571},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s11864-015-0338-4","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T23:53:04Z","timestamp":1428537184000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose-Dense Approaches to Ovarian Cancer Treatment"],"prefix":"10.1007","volume":"16","author":[{"given":"Noriyuki","family":"Katsumata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,10]]},"reference":[{"key":"338_CR1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","volume":"21","author":"T Thigpen","year":"2011","unstructured":"Thigpen T, du Bois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21:756\u201362.","journal-title":"Int J Gynecol Cancer"},{"key":"338_CR2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin vs conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Lancet Oncol. 2013;14:1020\u20136.","journal-title":"Lancet Oncol"},{"key":"338_CR3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week vs every 3\u00a0weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multi-center, open-label, phase 3 trial. Lancet Oncol. 2014;15:396\u2013405.","journal-title":"Lancet Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-015-0338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-015-0338-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-015-0338-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:34:29Z","timestamp":1559417669000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-015-0338-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,10]]},"references-count":3,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1007\/s11864-015-0338-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,10]]},"article-number":"21"}}